Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome

Basit Öğe Kaydı
dc.authoridElmas, Ahmet Taner/0000-0002-9749-6115
dc.authorwosidELMAS, Ahmet Taner/W-4101-2017
dc.authorwosidTabel, Yilmaz/AAF-9801-2020
dc.authorwosidElmas, Ahmet Taner/ABI-1338-2020
dc.contributor.authorElmas, Ahmet Taner
dc.contributor.authorTabel, Yilmaz
dc.contributor.authorElmas, Ozlem Nalbantoglu
dc.date.accessioned2024-08-04T20:37:45Z
dc.date.available2024-08-04T20:37:45Z
dc.date.issued2013
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, we aimed to evaluate short- and long-term effects of levamisole therapy in steroid-sensitive nephrotic syndrome (SSNS) in children. The study consisted of 29 SSNS patients who had been treated with levamisole for 12 months. Laboratory values and clinical data were analyzed for three separate periods for each patient: 1 year prior to the initiation of levamisole therapy (Pre-Lev), during 1 year of levamisole therapy (During-Lev), and the year following cessation of levamisole therapy (End-Lev). The level of proteinuria fell from median 135.0 (24.0-633.0) mg/h/m(2) Pre-Lev to median 4.4 (2.4-654.0) mg/h/m(2) During-Lev and median 4.8 (2.2-105.0) mg/h/m(2) End-Lev (p = 0.0001, for each). Median relapse frequency fell from 4.0 (3.0-8.0) relapses/patient per year Pre-Lev to 0.0 (0.0-2.0) During-Lev (p = 0.0001) with 23/29 patients having no relapse and 0.0 (0.0-1.0) End-Lev (p = 0.0001) with 18/29 patients without relapse. During-Lev, all children had marked diminution in annual steroid burden from a median of 5582.0 (2137.0-17340.0) mg/m(2) per year Pre-Lev to 2166.0 (840.0-9325.0) mg/m(2) per year (p = 0.0001). End-Lev, the annual steroid burden also continued to fall, to 0.0 (0.0-5386.0) mg/m(2) per year (p = 0.0001). The age and duration of NS were significantly higher in the children with relapses than in the children with sustained remission (p = 0.009 and p = 0.014, respectively). The side effects that are expected during levamisole therapy did not occur in our patients. Thus, our study showed that levamisole is a safe and effective steroid-sparing agent, with long-lasting effect even 12 months after withdrawal.en_US
dc.identifier.doi10.1007/s11255-012-0241-x
dc.identifier.endpage1055en_US
dc.identifier.issn0301-1623
dc.identifier.issn1573-2584
dc.identifier.issue4en_US
dc.identifier.pmid22826143en_US
dc.identifier.scopus2-s2.0-84881478473en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1047en_US
dc.identifier.urihttps://doi.org/10.1007/s11255-012-0241-x
dc.identifier.urihttps://hdl.handle.net/11616/96167
dc.identifier.volume45en_US
dc.identifier.wosWOS:000322718000020en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofInternational Urology and Nephrologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChilden_US
dc.subjectLevamisoleen_US
dc.subjectFrequently relapsing nephrotic syndromeen_US
dc.subjectSteroid-dependent nephrotic syndromeen_US
dc.subjectRemission rateen_US
dc.titleShort- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndromeen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu